Compare DuPont de Nemours Inc (DD) vs Heron Therapeutics Inc (HRTX) Price & Performance

DuPont (DD) trades at $132.66, down 1.5% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (35.01%) but negative net income margin (-0.42%) and ROE (-0.16%). Analyst consensus remains bullish with a $227.20 price target (71% upside), though the company faces legal challenges and persistent net cash outflows. Recent developments include water technology upgrades and a 3:1 reverse stock split effective June 2026.

While analyst optimism and valuation discount to price target suggest potential upside, investors face significant risks including ongoing litigation over 'forever chemicals,' weak profitability trends, and concerning cash flow patterns. The stock's current technical weakness near support levels requires careful monitoring of Q2 2026 earnings results due July 2026.

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.